REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Gastroesophageal Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. The varying nature of gastroesophageal cancer, spanning from localized, indolent tumors to aggressive, metastatic forms, coupled with the emergence of resistance to established treatments, emphasizes the urgent requirement for ongoing research and clinical…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Colorectal Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. The complexity of colorectal cancer, spanning from localized, slow-growing tumors to aggressive forms, necessitates a diverse approach in both research and clinical management. Recent advancements in understanding its molecular and genetic underpinnings have…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Breast Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. Metastatic breast cancer continues to be a significant health challenge in oncology. As the most common cancer in women worldwide, it imposes substantial healthcare burdens and necessitates continuous research and innovation in treatment…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: NSCL Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. NSCLC’s complex nature, characterized by diverse pathological profiles and variable responses to treatments, underscores the need for ongoing research and innovation in treatment strategies. OXON has analyzed the results of the studies presented…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Prostate Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. As the second most common cancer in men worldwide, prostate cancer poses substantial healthcare burdens and necessitates continuous research and innovation in treatment strategies. OXON has analyzed the results of the trials presented…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Non-Prostate Urothelial Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. In the dynamic landscape of oncology, non-prostate urothelial cancers, encompassing bladder and urinary tract malignancies, present unique challenges in clinical management. By synthesizing insights from the ESMO 2023 conference and broader oncological…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Melanoma White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. Advancements in melanoma therapies presented at ESMO 2023 mark a shift, where the integration of innovative treatments with real-world data is paving the way for more personalized and effective care in melanoma. In this…
Read more
FREE LIVE DEBATE “When can RWE be relied on to complement or replace evidence from RCTs to guide clinical decisions?” By leading Professors from Harvard, Oxford, London DATE: October 5, 2023, at 5pm CEST | 4pm UK time | 11am EST. OXON Epidemiology bring together for this live debate two leading proponents who believe that…
Read more
OXON’s RWE solutions at the 39th International Conference on PharmacoEpidemiology, ICPE 2023. The Global Home for the Science of Real-World August 23-27, 2023. | Halifax Convention Centre | Halifax, Nova Scotia, Canada OXON will be supporting ICPE 2023 as an exhibitor, presenting its expertise in RWE during this virtual and in-person interactional scientific event as well…
Read more
Nawab Qizilbash will be speaking at the Global Clinical Trial Connect 2023 Conference 10- 11 May 2023 Nawab Qizilbash, Senior Clinical Epidemiologist and Head of OXON will be participating at the Global Clinical Trials Connect 2023 Conference on Wednesday, 10 May at 11:20h BST | 12:20h CEST. Under the title of “The complementary roles of…
Read more
